## Innoviva (INVA) — filings-driven deep dive (royalties + hospital anti-infectives + strategic capital allocation) ### Executive takeaway (what matters most) Innoviva is best understood as **two cash-flow engines plus a capital allocator**: (1) a **respiratory royalty stream from GSK** (RELVAR/BREO + ANORO) and (2) a **hospital-focused critical care / infectious disease (“IST”) commercial platform** (GIAPREZA, XERAVA, XACDURO, and now ZEVTERA in the U.S.), with (3) **meaningful balance-sheet and investment-portfolio volatility** via strategic investments (e.g., Armata) and the ISP Fund structure. ["royalty portfolio contains respiratory assets partnered with GSK"](0000950170-25-027864|0) ["critical care and infectious disease operating platform"](0000950170-25-027864|0) ["Changes in fair values"](0000950170-25-027864|0) --- ## 1) “Choose your lens” navigation (interactive) You can read INVA through any of these “lenses” (they’re all supported by the same disclosures): 1. **Royalty annuity lens (GSK):** durability, pricing pressure, generic threats, and how the royalty math works. ["entitled to receive royalties from GSK"](0000950170-25-027864|0) 2. **Hospital commercial build lens (IST):** whether the anti-infective franchise is scaling and what launches (ZEVTERA) mean. ["commercial and marketed products include"](0000950170-25-027864|0) 3. **Capital allocation lens:** debt stack + buybacks + investment portfolio (and the P&L volatility it creates). ["focus on capital allocation"](0000950170-25-027864|0) ["repurchase program"](0000950170-25-027864|0) I’ll cover all three, but keep that mental model in mind. --- ## 2) Business model map (what INVA *is*, per its filings) ### 2.1 Core structure (as described in the 10‑K) Innoviva describes itself as a company with: - a **core royalties portfolio**, - a **critical care and infectious disease platform (IST)**, and - **strategic investments** in other healthcare assets. ["core royalties portfolio"](0000950170-25-027864|0) ["Innoviva Specialty Therapeutics (“IST”)"](0000950170-25-027864|0) ["strategic healthcare assets"](0000950170-25-027864|0) ### 2.2 The two operating cash generators **(A) GSK royalties (respiratory):** RELVAR/BREO and ANORO (and historically TRELEGY via TRC until sold). ["RELVAR®/BREO® ELLIPTA®"](0000950170-25-027864|0) ["ANORO® ELLIPTA®"](0000950170-25-027864|0) ["sold our 15% ownership interest in TRC"](0000950170-25-027864|0) **(B) Net product sales (IST hospital products):** GIAPREZA, XERAVA, XACDURO; plus ZEVTERA rights (Basilea) and pipeline zoliflodacin. ["GIAPREZA®"](0000950170-25-027864|0) ["XERAVA®"](0000950170-25-027864|0) ["XACDURO®"](0000950170-25-027864|0) ["exclusive distribution and license agreement with Basilea"](0000950170-25-027864|0) ["submit a New Drug Application (“NDA”) for zoliflodacin"](0000950170-25-027864|0) --- ## 3) Royalty engine (GSK): how the economics actually work ### 3.1 Royalty terms (the “math” you underwrite) Per the 10‑K, Innoviva’s RELVAR/BREO royalty is: **15% on the first $3.0B of annual global net sales, and 5% above $3.0B**. ["15% on the first $3.0 billion"](0000950170-25-027864|0) ANORO royalties are **tiered upward in a range from 6.5% to 10%**. ["tier upward at a range from 6.5% to 10%"](0000950170-25-027864|0) **Important accounting nuance:** royalties from GSK are reported **net of amortization of “capitalized fees paid”** (milestones previously paid to GSK). ["royalty revenue, net of amortization of capitalized fees paid"](0000950170-25-027864|0) ### 3.2 What the most recent 10‑Q says about current royalty split INVA discloses net revenue from the GSK collaboration split between RELVAR/BREO and ANORO (Q3 2025 and 9M 2025). ["Royalties - RELVAR/BREO"](0001193125-25-267040|0) ["Royalties - ANORO"](0001193125-25-267040|0) ### 3.3 The *real* strategic risk: dependence + pricing/generic pressure INVA’s 10‑K is explicit that **most revenue is derived from GSK** and near-term success depends on GSK commercialization. ["derive most of our revenues from GSK"](0000950170-25-027864|0) It also flags that **generics (and respiratory pricing pressure / PBMs)** can reduce net sales and therefore royalties. ["generic products… compete"](0000950170-25-027864|0) ["PBMs… increased discount levels"](0000950170-25-027864|0) **Analyst framing:** the royalty stream is high-margin and relatively low operating cost, but **you are underwriting GSK execution + respiratory market structure** more than Innoviva’s own go-to-market. --- ## 4) IST / hospital commercial engine: the product portfolio and trajectory ### 4.1 Net product sales by product (10‑K) This is one of the cleanest “is the platform scaling?” tables in the filing: | Net product sales (USD mm) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | GIAPREZA | 55.037 ["GIAPREZA®… 55,037"](0000950170-25-027864|0) | 41.294 ["GIAPREZA®… 41,294"](0000950170-25-027864|0) | 14.214 ["GIAPREZA®… 14,214"](0000950170-25-027864|0) | | XERAVA | 21.385 ["XERAVA®… 21,385"](0000950170-25-027864|0) | 17.320 ["XERAVA®… 17,320"](0000950170-25-027864|0) | 5.480 ["XERAVA®… 5,480"](0000950170-25-027864|0) | | XACDURO | 21.070 ["XACDURO®… 21,070"](0000950170-25-027864|0) | 2.003 ["XACDURO®… 2,003"](0000950170-25-027864|0) | 0.000 ["XACDURO®… —"](0000950170-25-027864|0) | | **Total** | **97.492** ["Total net product sales… 97,492"](0000950170-25-027864|0) | **60.617** ["Total net product sales… 60,617"](0000950170-25-027864|0) | **19.694** ["Total net product sales… 19,694"](0000950170-25-027864|0) | **Quick interpretation (computed):** Total net product sales rose from **$60.617m → $97.492m (+61%)** in FY2024. ["Total net product sales… 97,492"](0000950170-25-027864|0) ["Total net product sales… 60,617"](0000950170-25-027864|0) ### 4.2 Geographic mix (important for “platform quality”) For FY2024, INVA says net product sales were **~83% U.S. and 17% rest of world**. ["approximately 83%… U.S. and 17%"](0000950170-25-027864|0) ### 4.3 ZEVTERA: from “rights acquired” (10‑K) to “commercial launch” (10‑Q) - **10‑K (FY2024):** INVA entered a Basilea deal for U.S. commercialization, paying **$4.0m upfront**, plus tiered royalties/milestones, and anticipated commercialization in **mid‑2025**. ["$4.0 million upfront payment"](0000950170-25-027864|0) ["anticipate commercializing… mid-year 2025"](0000950170-25-027864|0) - **10‑Q (Q3 2025):** ZEVTERA was **commercially launched in the U.S. in July 2025**. ["commercially launched in the U.S. in July 2025"](0001193125-25-267040|0) **Analyst framing:** ZEVTERA adds a potentially meaningful hospital product, but it also likely introduces **launch investment**, supply/royalty obligations to Basilea, and execution risk (formulary access, hospital protocols). ### 4.4 Customer concentration (a hospital-commercial reality) The 10‑K states **three customers account for ~31%, 24%, and 24%** of FY2024 net product sales. ["31%, 24% and 24%"](0000950170-25-027864|0) --- ## 5) Financial performance: a filings-only “model spine” ## 5.1 Income statement snapshot (FY2022–FY2024, 10‑K) Below is the consolidated view that ties the two engines together (royalties + product sales) plus the investment volatility. | (USD mm) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Royalty revenue (net) | 241.733 ["Royalty revenue… 241,733"](0000950170-25-027864|0) | 238.846 ["Royalty revenue… 238,846"](0000950170-25-027864|0) | 311.645 ["Royalty revenue… 311,645"](0000950170-25-027864|0) | | Net product sales | 97.492 ["Net product sales… 97,492"](0000950170-25-027864|0) | 60.617 ["Net product sales… 60,617"](0000950170-25-027864|0) | 19.694 ["Net product sales… 19,694"](0000950170-25-027864|0) | | License & other revenue | 19.486 ["License and other revenue… 19,486"](0000950170-25-027864|0) | 11.000 ["License and other revenue… 11,000"](0000950170-25-027864|0) | 0.000 ["License and other revenue… —"](0000950170-25-027864|0) | | **Total revenue** | **358.711** ["Total revenue… 358,711"](0000950170-25-027864|0) | **310.463** ["Total revenue… 310,463"](0000950170-25-027864|0) | **331.339** ["Total revenue… 331,339"](0000950170-25-027864|0) | | Net income | 23.392 ["Net income… 23,392"](0000950170-25-027864|0) | 179.722 ["Net income… 179,722"](0000950170-25-027864|0) | 220.262 ["Net income… 220,262"](0000950170-25-027864|0) | **Why net income swings so much:** the 10‑K includes large “changes in fair values” lines (equity method and other long-term investments) that can meaningfully move GAAP earnings. ["Changes in fair values… 64,253"](0000950170-25-027864|0) ["Changes in fair value… 59,161"](0000950170-25-027864|0) ## 5.2 Cash flow (10‑K) Operating cash flow is a cleaner indicator of the underlying engines than GAAP net income: | (USD mm) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Net cash from operating activities | 188.690 ["Net cash provided… 188,690"](0000950170-25-027864|0) | 141.064 ["Net cash provided… 141,064"](0000950170-25-027864|0) | 201.726 ["Net cash provided… 201,726"](0000950170-25-027864|0) | | Ending cash & equivalents | 304.964 ["Cash and cash equivalents… 304,964"](0000950170-25-027864|0) | 193.513 ["Cash and cash equivalents… 193,513"](0000950170-25-027864|0) | 291.049 ["Cash and cash equivalents… 291,049"](0000950170-25-027864|0) | --- ## 6) Balance sheet & capital structure (what the balance sheet is “telling you”) ### 6.1 Year-end balance sheet highlights (10‑K) INVA finished FY2024 with **$305.0m cash** and **$453.5m total debt** (convertible notes). ["Cash and cash equivalents… 304,964"](0000950170-25-027864|0) ["$453.5 million in total debt outstanding"](0000950170-25-027864|0) Selected balance sheet items (USD mm, FY2024 vs FY2023): | Item | FY2024 | FY2023 | |---|---:|---:| | Cash & equivalents | 304.964 ["Cash and cash equivalents… 304,964"](0000950170-25-027864|0) | 193.513 ["Cash and cash equivalents… 193,513"](0000950170-25-027864|0) | | Total assets | 1,301.060 ["Total assets… 1,301,060"](0000950170-25-027864|0) | 1,243.507 ["Total assets… 1,243,507"](0000950170-25-027864|0) | | Long-term debt (net) | 256.316 ["Long-term debt… 256,316"](0000950170-25-027864|0) | 446.234 ["Long-term debt… 446,234"](0000950170-25-027864|0) | | Current convertible notes due 2025 (net) | 192.028 ["Convertible notes, due 2025… 192,028"](0000950170-25-027864|0) | 0.000 ["Convertible notes, due 2025… —"](0000950170-25-027864|0) | ### 6.2 Debt maturity map (10‑K) + what changed in 2025 (10‑Q) **10‑K maturity schedule (as of 12/31/2024):** 2025 Notes ($192.5m) and 2028 Notes ($261.0m). ["Debt Maturities"](0000950170-25-027864|0) **10‑Q (Q3 2025):** INVA discloses **“2025 Notes converted to common stock”** and shows **$192.475m** as a non-cash financing activity. ["2025 Notes converted to common stock… 192,475"](0001193125-25-267040|0) **Analyst framing:** the conversion reduces refinancing / maturity risk, but can introduce dilution (depending on settlement method and hedges). --- ## 7) Capital allocation: buybacks, dividends, and the “investment portfolio” factor ### 7.1 Buybacks (a big part of the INVA story) INVA’s 10‑K discloses a **$100m share repurchase program authorized Oct 31, 2022** and details repurchases through completion in April 2024. ["authorized a share repurchase program… $100.0 million"](0000950170-25-027864|0) ["repurchase program was completed in April 2024"](0000950170-25-027864|0) Key disclosed repurchase amounts: - FY2023: **$76.5m** repurchased at avg **$12.39**. ["$76.5 million"](0000950170-25-027864|0) ["average price of $12.39"](0000950170-25-027864|0) - Jan–Apr 2024: **$14.9m** at avg **$15.12**. ["$14.9 million"](0000950170-25-027864|0) ["average price of $15.12"](0000950170-25-027864|0) ### 7.2 Dividends: explicitly not the plan (per 10‑K) INVA states it **has not paid dividends since Sept 30, 2015** and does not anticipate stock dividends in the foreseeable future. ["have not paid any cash dividends… since September 30, 2015"](0000950170-25-027864|0) ["does not anticipate declaring any stock dividends"](0000950170-25-027864|0) ### 7.3 The ISP Fund & strategic investments (Sarissa / Armata): why earnings can look “noisy” INVA describes ISP Fund LP (managed via Sarissa relationships) and notes an election to **unwind capital accounts with expected distributions through April 2026**. ["ISP Fund LP"](0000950170-25-027864|0) ["expect to receive distributions… through April 2026"](0000950170-25-027864|0) It also discloses large fair value changes in Armata holdings across years. ["Armata common stock… fair values"](0000950170-25-027864|0) **Analyst framing:** even if operations are steady, reported GAAP earnings may swing with market marks on strategic stakes. --- ## 8) Risk register (the ones the filings keep emphasizing) ### 8.1 Concentration risk: “GSK is the center of gravity” INVA states it derives most revenues from GSK and depends on GSK commercialization of RELVAR/BREO and ANORO. ["derive most of our revenues from GSK"](0000950170-25-027864|0) ### 8.2 Respiratory competition / generics / pricing pressure The 10‑K describes generic competition dynamics and pricing pressure (PBMs, government actions). ["generic products"](0000950170-25-027864|0) ["PBMs… increased discount levels"](0000950170-25-027864|0) ### 8.3 Debt / capital structure constraints INVA highlights meaningful convertible debt and potential fundamental-change puts. ["$453.5 million in total debt outstanding"](0000950170-25-027864|0) ["Holders… may require us to purchase"](0000950170-25-027864|0) ### 8.4 Hospital-commercial execution + reimbursement mechanics The 10‑K notes that hospital-administered drugs are often purchased by hospitals and reimbursed indirectly (DRG systems), typically slowing adoption. ["drugs… administered in the hospital"](0000950170-25-027864|0) ### 8.5 GIAPREZA generic litigation: meaningful clarity event (10‑Q) In Q3 2025 10‑Q, INVA discloses a **Feb 18, 2025 settlement agreement** for the Hatch‑Waxman litigation, with a license commencing in the **early 2030s** (subject to DOJ/FTC review). ["entered into a settlement agreement"](0001193125-25-267040|0) ["commencing in the early 2030s"](0001193125-25-267040|0) ["subject to review by… DOJ… FTC"](0001193125-25-267040|0) --- ## 9) What I would monitor every quarter (a practical checklist) 1. **Royalty split + trajectory:** RELVAR/BREO vs ANORO, and net royalty revenue trend. ["Royalties - RELVAR/BREO"](0001193125-25-267040|0) 2. **Net product sales scale:** total + product mix (GIAPREZA / XERAVA / XACDURO / ZEVTERA). ["Net product sales"](0001193125-25-267040|0) ["beginning in the second quarter of 2025, ZEVTERA"](0001193125-25-267040|0) 3. **Launch spending vs. contribution:** watch SG&A and gross profit alongside ZEVTERA ramp. ["Selling, general and administrative"](0001193125-25-267040|0) 4. **Investment marks:** equity method / long-term investment fair value swings. ["Changes in fair values"](0001193125-25-267040|0) 5. **Balance sheet / debt events:** conversion / maturity handling. ["2025 Notes converted to common stock"](0001193125-25-267040|0) --- If you want, I can follow up by producing a **one-page “INVA underwriting template”** (drivers + sensitivities + bear/base/bull thesis structure) strictly from these same filings—no extra inputs needed.

## Innoviva (INVA) — filings-driven deep dive (royalties + hospital anti-infectives + strategic capital allocation) ### Executive takeaway (what matters most) Innoviva is best understood as **two cash-flow engines plus a capital allocator**: (1) a **respiratory royalty stream from GSK** (RELVAR/BREO + ANORO) and (2) a **hospital-focused critical care / infectious disease (“IST”) commercial platform** (GIAPREZA, XERAVA, XACDURO, and now ZEVTERA in the U.S.), with (3) **meaningful balance-sheet and investment-portfolio volatility** via strategic investments (e.g., Armata) and the ISP Fund structure. ["royalty portfolio contains respiratory assets partnered with GSK"](0000950170-25-027864|0) ["critical care and infectious disease operating platform"](0000950170-25-027864|0) ["Changes in fair values"](0000950170-25-027864|0) --- ## 1) “Choose your lens” navigation (interactive) You can read INVA through any of these “lenses” (they’re all supported by the same disclosures): 1. **Royalty annuity lens (GSK):** durability, pricing pressure, generic threats, and how the royalty math works. ["entitled to receive royalties from GSK"](0000950170-25-027864|0) 2. **Hospital commercial build lens (IST):** whether the anti-infective franchise is scaling and what launches (ZEVTERA) mean. ["commercial and marketed products include"](0000950170-25-027864|0) 3. **Capital allocation lens:** debt stack + buybacks + investment portfolio (and the P&L volatility it creates). ["focus on capital allocation"](0000950170-25-027864|0) ["repurchase program"](0000950170-25-027864|0) I’ll cover all three, but keep that mental model in mind. --- ## 2) Business model map (what INVA *is*, per its filings) ### 2.1 Core structure (as described in the 10‑K) Innoviva describes itself as a company with: - a **core royalties portfolio**, - a **critical care and infectious disease platform (IST)**, and - **strategic investments** in other healthcare assets. ["core royalties portfolio"](0000950170-25-027864|0) ["Innoviva Specialty Therapeutics (“IST”)"](0000950170-25-027864|0) ["strategic healthcare assets"](0000950170-25-027864|0) ### 2.2 The two operating cash generators **(A) GSK royalties (respiratory):** RELVAR/BREO and ANORO (and historically TRELEGY via TRC until sold). ["RELVAR®/BREO® ELLIPTA®"](0000950170-25-027864|0) ["ANORO® ELLIPTA®"](0000950170-25-027864|0) ["sold our 15% ownership interest in TRC"](0000950170-25-027864|0) **(B) Net product sales (IST hospital products):** GIAPREZA, XERAVA, XACDURO; plus ZEVTERA rights (Basilea) and pipeline zoliflodacin. ["GIAPREZA®"](0000950170-25-027864|0) ["XERAVA®"](0000950170-25-027864|0) ["XACDURO®"](0000950170-25-027864|0) ["exclusive distribution and license agreement with Basilea"](0000950170-25-027864|0) ["submit a New Drug Application (“NDA”) for zoliflodacin"](0000950170-25-027864|0) --- ## 3) Royalty engine (GSK): how the economics actually work ### 3.1 Royalty terms (the “math” you underwrite) Per the 10‑K, Innoviva’s RELVAR/BREO royalty is: **15% on the first $3.0B of annual global net sales, and 5% above $3.0B**. ["15% on the first $3.0 billion"](0000950170-25-027864|0) ANORO royalties are **tiered upward in a range from 6.5% to 10%**. ["tier upward at a range from 6.5% to 10%"](0000950170-25-027864|0) **Important accounting nuance:** royalties from GSK are reported **net of amortization of “capitalized fees paid”** (milestones previously paid to GSK). ["royalty revenue, net of amortization of capitalized fees paid"](0000950170-25-027864|0) ### 3.2 What the most recent 10‑Q says about current royalty split INVA discloses net revenue from the GSK collaboration split between RELVAR/BREO and ANORO (Q3 2025 and 9M 2025). ["Royalties - RELVAR/BREO"](0001193125-25-267040|0) ["Royalties - ANORO"](0001193125-25-267040|0) ### 3.3 The *real* strategic risk: dependence + pricing/generic pressure INVA’s 10‑K is explicit that **most revenue is derived from GSK** and near-term success depends on GSK commercialization. ["derive most of our revenues from GSK"](0000950170-25-027864|0) It also flags that **generics (and respiratory pricing pressure / PBMs)** can reduce net sales and therefore royalties. ["generic products… compete"](0000950170-25-027864|0) ["PBMs… increased discount levels"](0000950170-25-027864|0) **Analyst framing:** the royalty stream is high-margin and relatively low operating cost, but **you are underwriting GSK execution + respiratory market structure** more than Innoviva’s own go-to-market. --- ## 4) IST / hospital commercial engine: the product portfolio and trajectory ### 4.1 Net product sales by product (10‑K) This is one of the cleanest “is the platform scaling?” tables in the filing: | Net product sales (USD mm) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | GIAPREZA | 55.037 ["GIAPREZA®… 55,037"](0000950170-25-027864|0) | 41.294 ["GIAPREZA®… 41,294"](0000950170-25-027864|0) | 14.214 ["GIAPREZA®… 14,214"](0000950170-25-027864|0) | | XERAVA | 21.385 ["XERAVA®… 21,385"](0000950170-25-027864|0) | 17.320 ["XERAVA®… 17,320"](0000950170-25-027864|0) | 5.480 ["XERAVA®… 5,480"](0000950170-25-027864|0) | | XACDURO | 21.070 ["XACDURO®… 21,070"](0000950170-25-027864|0) | 2.003 ["XACDURO®… 2,003"](0000950170-25-027864|0) | 0.000 ["XACDURO®… —"](0000950170-25-027864|0) | | **Total** | **97.492** ["Total net product sales… 97,492"](0000950170-25-027864|0) | **60.617** ["Total net product sales… 60,617"](0000950170-25-027864|0) | **19.694** ["Total net product sales… 19,694"](0000950170-25-027864|0) | **Quick interpretation (computed):** Total net product sales rose from **$60.617m → $97.492m (+61%)** in FY2024. ["Total net product sales… 97,492"](0000950170-25-027864|0) ["Total net product sales… 60,617"](0000950170-25-027864|0) ### 4.2 Geographic mix (important for “platform quality”) For FY2024, INVA says net product sales were **~83% U.S. and 17% rest of world**. ["approximately 83%… U.S. and 17%"](0000950170-25-027864|0) ### 4.3 ZEVTERA: from “rights acquired” (10‑K) to “commercial launch” (10‑Q) - **10‑K (FY2024):** INVA entered a Basilea deal for U.S. commercialization, paying **$4.0m upfront**, plus tiered royalties/milestones, and anticipated commercialization in **mid‑2025**. ["$4.0 million upfront payment"](0000950170-25-027864|0) ["anticipate commercializing… mid-year 2025"](0000950170-25-027864|0) - **10‑Q (Q3 2025):** ZEVTERA was **commercially launched in the U.S. in July 2025**. ["commercially launched in the U.S. in July 2025"](0001193125-25-267040|0) **Analyst framing:** ZEVTERA adds a potentially meaningful hospital product, but it also likely introduces **launch investment**, supply/royalty obligations to Basilea, and execution risk (formulary access, hospital protocols). ### 4.4 Customer concentration (a hospital-commercial reality) The 10‑K states **three customers account for ~31%, 24%, and 24%** of FY2024 net product sales. ["31%, 24% and 24%"](0000950170-25-027864|0) --- ## 5) Financial performance: a filings-only “model spine” ## 5.1 Income statement snapshot (FY2022–FY2024, 10‑K) Below is the consolidated view that ties the two engines together (royalties + product sales) plus the investment volatility. | (USD mm) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Royalty revenue (net) | 241.733 ["Royalty revenue… 241,733"](0000950170-25-027864|0) | 238.846 ["Royalty revenue… 238,846"](0000950170-25-027864|0) | 311.645 ["Royalty revenue… 311,645"](0000950170-25-027864|0) | | Net product sales | 97.492 ["Net product sales… 97,492"](0000950170-25-027864|0) | 60.617 ["Net product sales… 60,617"](0000950170-25-027864|0) | 19.694 ["Net product sales… 19,694"](0000950170-25-027864|0) | | License & other revenue | 19.486 ["License and other revenue… 19,486"](0000950170-25-027864|0) | 11.000 ["License and other revenue… 11,000"](0000950170-25-027864|0) | 0.000 ["License and other revenue… —"](0000950170-25-027864|0) | | **Total revenue** | **358.711** ["Total revenue… 358,711"](0000950170-25-027864|0) | **310.463** ["Total revenue… 310,463"](0000950170-25-027864|0) | **331.339** ["Total revenue… 331,339"](0000950170-25-027864|0) | | Net income | 23.392 ["Net income… 23,392"](0000950170-25-027864|0) | 179.722 ["Net income… 179,722"](0000950170-25-027864|0) | 220.262 ["Net income… 220,262"](0000950170-25-027864|0) | **Why net income swings so much:** the 10‑K includes large “changes in fair values” lines (equity method and other long-term investments) that can meaningfully move GAAP earnings. ["Changes in fair values… 64,253"](0000950170-25-027864|0) ["Changes in fair value… 59,161"](0000950170-25-027864|0) ## 5.2 Cash flow (10‑K) Operating cash flow is a cleaner indicator of the underlying engines than GAAP net income: | (USD mm) | FY2024 | FY2023 | FY2022 | |---|---:|---:|---:| | Net cash from operating activities | 188.690 ["Net cash provided… 188,690"](0000950170-25-027864|0) | 141.064 ["Net cash provided… 141,064"](0000950170-25-027864|0) | 201.726 ["Net cash provided… 201,726"](0000950170-25-027864|0) | | Ending cash & equivalents | 304.964 ["Cash and cash equivalents… 304,964"](0000950170-25-027864|0) | 193.513 ["Cash and cash equivalents… 193,513"](0000950170-25-027864|0) | 291.049 ["Cash and cash equivalents… 291,049"](0000950170-25-027864|0) | --- ## 6) Balance sheet & capital structure (what the balance sheet is “telling you”) ### 6.1 Year-end balance sheet highlights (10‑K) INVA finished FY2024 with **$305.0m cash** and **$453.5m total debt** (convertible notes). ["Cash and cash equivalents… 304,964"](0000950170-25-027864|0) ["$453.5 million in total debt outstanding"](0000950170-25-027864|0) Selected balance sheet items (USD mm, FY2024 vs FY2023): | Item | FY2024 | FY2023 | |---|---:|---:| | Cash & equivalents | 304.964 ["Cash and cash equivalents… 304,964"](0000950170-25-027864|0) | 193.513 ["Cash and cash equivalents… 193,513"](0000950170-25-027864|0) | | Total assets | 1,301.060 ["Total assets… 1,301,060"](0000950170-25-027864|0) | 1,243.507 ["Total assets… 1,243,507"](0000950170-25-027864|0) | | Long-term debt (net) | 256.316 ["Long-term debt… 256,316"](0000950170-25-027864|0) | 446.234 ["Long-term debt… 446,234"](0000950170-25-027864|0) | | Current convertible notes due 2025 (net) | 192.028 ["Convertible notes, due 2025… 192,028"](0000950170-25-027864|0) | 0.000 ["Convertible notes, due 2025… —"](0000950170-25-027864|0) | ### 6.2 Debt maturity map (10‑K) + what changed in 2025 (10‑Q) **10‑K maturity schedule (as of 12/31/2024):** 2025 Notes ($192.5m) and 2028 Notes ($261.0m). ["Debt Maturities"](0000950170-25-027864|0) **10‑Q (Q3 2025):** INVA discloses **“2025 Notes converted to common stock”** and shows **$192.475m** as a non-cash financing activity. ["2025 Notes converted to common stock… 192,475"](0001193125-25-267040|0) **Analyst framing:** the conversion reduces refinancing / maturity risk, but can introduce dilution (depending on settlement method and hedges). --- ## 7) Capital allocation: buybacks, dividends, and the “investment portfolio” factor ### 7.1 Buybacks (a big part of the INVA story) INVA’s 10‑K discloses a **$100m share repurchase program authorized Oct 31, 2022** and details repurchases through completion in April 2024. ["authorized a share repurchase program… $100.0 million"](0000950170-25-027864|0) ["repurchase program was completed in April 2024"](0000950170-25-027864|0) Key disclosed repurchase amounts: - FY2023: **$76.5m** repurchased at avg **$12.39**. ["$76.5 million"](0000950170-25-027864|0) ["average price of $12.39"](0000950170-25-027864|0) - Jan–Apr 2024: **$14.9m** at avg **$15.12**. ["$14.9 million"](0000950170-25-027864|0) ["average price of $15.12"](0000950170-25-027864|0) ### 7.2 Dividends: explicitly not the plan (per 10‑K) INVA states it **has not paid dividends since Sept 30, 2015** and does not anticipate stock dividends in the foreseeable future. ["have not paid any cash dividends… since September 30, 2015"](0000950170-25-027864|0) ["does not anticipate declaring any stock dividends"](0000950170-25-027864|0) ### 7.3 The ISP Fund & strategic investments (Sarissa / Armata): why earnings can look “noisy” INVA describes ISP Fund LP (managed via Sarissa relationships) and notes an election to **unwind capital accounts with expected distributions through April 2026**. ["ISP Fund LP"](0000950170-25-027864|0) ["expect to receive distributions… through April 2026"](0000950170-25-027864|0) It also discloses large fair value changes in Armata holdings across years. ["Armata common stock… fair values"](0000950170-25-027864|0) **Analyst framing:** even if operations are steady, reported GAAP earnings may swing with market marks on strategic stakes. --- ## 8) Risk register (the ones the filings keep emphasizing) ### 8.1 Concentration risk: “GSK is the center of gravity” INVA states it derives most revenues from GSK and depends on GSK commercialization of RELVAR/BREO and ANORO. ["derive most of our revenues from GSK"](0000950170-25-027864|0) ### 8.2 Respiratory competition / generics / pricing pressure The 10‑K describes generic competition dynamics and pricing pressure (PBMs, government actions). ["generic products"](0000950170-25-027864|0) ["PBMs… increased discount levels"](0000950170-25-027864|0) ### 8.3 Debt / capital structure constraints INVA highlights meaningful convertible debt and potential fundamental-change puts. ["$453.5 million in total debt outstanding"](0000950170-25-027864|0) ["Holders… may require us to purchase"](0000950170-25-027864|0) ### 8.4 Hospital-commercial execution + reimbursement mechanics The 10‑K notes that hospital-administered drugs are often purchased by hospitals and reimbursed indirectly (DRG systems), typically slowing adoption. ["drugs… administered in the hospital"](0000950170-25-027864|0) ### 8.5 GIAPREZA generic litigation: meaningful clarity event (10‑Q) In Q3 2025 10‑Q, INVA discloses a **Feb 18, 2025 settlement agreement** for the Hatch‑Waxman litigation, with a license commencing in the **early 2030s** (subject to DOJ/FTC review). ["entered into a settlement agreement"](0001193125-25-267040|0) ["commencing in the early 2030s"](0001193125-25-267040|0) ["subject to review by… DOJ… FTC"](0001193125-25-267040|0) --- ## 9) What I would monitor every quarter (a practical checklist) 1. **Royalty split + trajectory:** RELVAR/BREO vs ANORO, and net royalty revenue trend. ["Royalties - RELVAR/BREO"](0001193125-25-267040|0) 2. **Net product sales scale:** total + product mix (GIAPREZA / XERAVA / XACDURO / ZEVTERA). ["Net product sales"](0001193125-25-267040|0) ["beginning in the second quarter of 2025, ZEVTERA"](0001193125-25-267040|0) 3. **Launch spending vs. contribution:** watch SG&A and gross profit alongside ZEVTERA ramp. ["Selling, general and administrative"](0001193125-25-267040|0) 4. **Investment marks:** equity method / long-term investment fair value swings. ["Changes in fair values"](0001193125-25-267040|0) 5. **Balance sheet / debt events:** conversion / maturity handling. ["2025 Notes converted to common stock"](0001193125-25-267040|0) --- If you want, I can follow up by producing a **one-page “INVA underwriting template”** (drivers + sensitivities + bear/base/bull thesis structure) strictly from these same filings—no extra inputs needed.